Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 studyJ Immunother Cancer 2022 Apr 01;10(4)e004419, NM Tannir, DC Cho, A Diab, M Sznol, MA Bilen, AV Balar, G Grignani, E Puente, L Tang, D Chien, U Hoch, A Choudhury, D Yu, SL Currie, MA Tagliaferri, J Zalevsky, AO Siefker-Radtke, ME Hurwitz
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.